CNTA logo

CNTA
Centessa Pharmaceuticals PLC - ADR

323
Mkt Cap
$5.89B
Volume
1.26M
52W High
$40.26
52W Low
$10.95
PE Ratio
-27.10
CNTA Fundamentals
Price
$39.48
Prev Close
$39.76
Open
$39.76
50D MA
$28.35
Beta
1.19
Avg. Volume
3.58M
EPS (Annual)
-$1.46
P/B
11.18
Rev/Employee
$127,415.70
$3,218.05
Loading...
Loading...
News
all
press releases
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, April 10, 2026 Insiders may stand to receive...
PR Newswire·1d ago
News Placeholder
More News
News Placeholder
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS...
PR Newswire·3d ago
News Placeholder
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders?
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, April 7, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...
PR Newswire·4d ago
News Placeholder
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy
Major M&A deals this week include: Eli Lilly's $7.8 billion purchase of Centessa Pharmaceuticals; Meanwhile, IO Biotech goes bankrupt.read more...
Benzinga·8d ago
News Placeholder
Centessa Pharmaceuticals (NASDAQ:CNTA) Receives "Neutral" Rating from Guggenheim
Guggenheim restated a "neutral" rating on shares of Centessa Pharmaceuticals in a report on Thursday...
MarketBeat·9d ago
News Placeholder
Centessa Pharmaceuticals (NASDAQ:CNTA) Earns "Market Perform" Rating from Leerink Partners
Leerink Partners reiterated a "market perform" rating and issued a $40.00 price target (up from $36.00) on shares of Centessa Pharmaceuticals in a research note on Wednesday...
MarketBeat·10d ago
News Placeholder
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centessa Pharmaceuticals plc (NASDAQ: CNTA)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centessa Pharmaceuticals plc (NASDAQ: CNTA) SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of...
PR Newswire·10d ago
News Placeholder
Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Large Volume Increase - Here's What Happened
Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Large Volume Increase - Here's Why...
MarketBeat·10d ago
News Placeholder
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
Lilly is set to acquire Centessa for up to $7.8B, adds sleep disorder drugs and advances its push to diversify beyond obesity and diabetes treatments.
Zacks·10d ago
News Placeholder
Centessa Pharmaceuticals (NASDAQ:CNTA) Lowered to "Hold" Rating by Stephens
Stephens cut Centessa Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday...
MarketBeat·10d ago
<
1
2
...
>

Latest CNTA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.